Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer

BACKGROUND: In the intent‐to‐treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Cascinu, Stefano, Bodoky, György, Muro, Kei, Van Cutsem, Eric, Oh, Sang Cheul, Folprecht, Gunnar, Ananda, Sumitra, Girotto, Gustavo, Wainberg, Zev A., Miron, Maria Luisa Limon, Ajani, Jaffer, Wei, Ran, Liepa, Astra M., Carlesi, Roberto, Emig, Michael, Ohtsu, Atsushi
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2020
Schlagworte:
Gastrointestinal Cancer
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930430/
https://ncbi.nlm.nih.gov/pubmed/33274542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13623
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge